

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 31/57, 9/12</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/27376</b> <b>(43) International Publication Date:</b> 12 September 1996 (12.09.96)
<b>(21) International Application Number:</b> PCT/GB96/00490 <b>(22) International Filing Date:</b> 1 March 1996 (01.03.96) <b>(30) Priority Data:</b> 9504265.1      3 March 1995 (03.03.95)      GB <b>(71) Applicant (for all designated States except US):</b> MEDEVA PLC [GB/GB]; 10 St. James's Street, London SW1A 1EF (GB). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> JONES, Julie, Irene [GB/GB]; 56 Townsend Lane, Harpenden, Hertfordshire AL5 2RG (GB). BAKER, Anthony, Richard [GB/GB]; Pucks Oak, Nightingale Avenue, West Horsley, Surrey KT24 6PB (GB). HALLS, Neil, Graham [AU/AU]; 31 Staldeford Avenue, Glen Waverley, VIC 3150 (AU). WAT- MOUGH, Peter [GB/GB]; 39 Amesbury Avenue, Grimsby, South Humberside DN33 3HT (GB). MARRIOTT, Peter [GB/GB]; 7 Fortuna Way, Grimsby, South Humberside DN37 9SH (GB). <b>(74) Agents:</b> HUTCHINS, Michael, Richard et al.; Fry Heath & Spence, The Old College, 53 High Street, Horley, Surrey RH6 7BN (GB).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> With international search report.	
<b>(54) Title:</b> CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION		
<b>(57) Abstract</b> <p>The present invention provides a foamable pharmaceutical composition comprising a corticosteroid active substance, a quick-break foaming agent, a propellant and a buffering agent. The quick-break foaming agent typically comprises an aliphatic alcohol, water, a fatty alcohol and surface active agent. The compositions of the invention can be used to treat various skin disease, and in particular scalp psoriasis.</p> <p style="text-align: center;">OH H<sub>2</sub>O</p> <p><i>Emulsion of claims 11 &amp; 26 which enhances the foam &amp; stability of solution.</i></p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

### CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION

The present invention relates to an improved composition for the topical application of corticosteroid active substances to the skin of a subject.

Corticosteroids, particularly in the form of the ester compounds, are used, inter alia, in the treatment of skin diseases in humans, such as eczema, infantile eczema, atopic dermatitis, dermatitis herpetiformis, contact dermatitis, seborrhoeic dermatitis, neurodermatitis, psoriasis and intertrigo. Formulations containing such active substances have conventionally been applied to the skin site in the form of alcoholic solutions, lotions or creams. However, there is a high degree of ineffectiveness with such formulations. Lotions and creams are generally too viscous to allow efficient penetration of the active to the epidermis, and solutions have a tendency to evaporate before penetrating the epidermis. In addition, conventional cream bases are irritating to the skin, particularly over the often long exposure that is required, and the fluidity of lotions often makes the physical application difficult to control. Moreover, it is necessary to rub such formulations into the target site to improve the penetration of the active substance into the epidermis, an action which itself produces irritation.

*Indication*

There has therefore been a very real need in the treatment of skin disorders requiring treatment with corticosteroids for improved formulations which target the most effective corticosteroid to the skin site with improved delivery of active, with decreased inconvenience and irritation, and increased ease of use for the patient.

The present invention provides an improved composition which addresses this need.

In one aspect, the present invention provides a foamable pharmaceutical composition comprising a corticosteroid active substance, a quick-break foaming agent, a propellant and a buffering agent.

Such a composition is applied to the skin site (after foaming) as a foam which is a thermophobic (heat sensitive) quick-break foam. On application to the skin, the composition is initially in the form of a mousse-like foam. The quick-break foam slowly breaks down at the skin temperature to a liquid to allow the alcohol and active substance to saturate the treatment site. Such a system provides enhanced penetration of the alcohol and active substance through the epidermis. Because the composition is supplied as a mousse, the semi-rigid behaviour of the composite makes it easier to handle and physically control. The foamed composition, when applied, provides a thick ball of foam which disintegrates easily when spread, allowing proper coverage of the skin site to be treated without premature evaporation of the solvent. It has been found important to include a buffering agent in the composition to stabilize the active isomer of the corticosteroid active substance in the complex foamable composition, otherwise the complex interactions within the foamable composition may result in the instability of the more active isomer.

Use of a quick-break foaming agent is required in the present invention. Such agents are known. Suitable quick-break foaming agents in the present invention are those described in Australian Patent No. 463216 and International Patent Application WO 85/01876. It is generally preferred that the quick-breaking foaming agent comprises an aliphatic alcohol, water, a fatty alcohol and a surface active agent. Particularly preferred is a quick-break foaming agent having the following composition:

- (a) an aliphatic alc hol, pr ferably in amounts of 40-90% w/w composition, more preferably 55-70% w/w, especially 57-59% w/w;
- (b) water, preferably in amounts of 10-40% w/w;
- (c) at least one fatty alcohol, preferably in amounts of 0.5-10% w/w; and
- (d) a surface active agent, preferably an ethoxylated sorbitan ester (as emulsifier), typically in amounts of 0.1-15% w/w.

In the quick-break foaming agent, the fatty alcohol may be chosen from, for example, cetyl, stearyl, lauryl, myristyl and palmityl alcohols and mixtures of two or more thereof. Mixtures of cetyl alcohol and a stearyl alcohol such as octadecan-1-ol have been found to be particularly preferred; the ratio between these two components may be adjusted to maintain foam viscosity throughout the broadest possible temperature range. In this situation, the stearyl alcohol maintains the viscosity at temperatures above 20°C whilst cetyl alcohol maintains the viscosity below 20°C.

The aliphatic alcohol may preferably be chosen from methyl, ethyl, isopropyl and butyl alcohols, and mixtures of two or more thereof. Ethanol has been found to be particularly preferred.

Surface active agents utilised in the quick-break foaming agent may preferably be chosen from ethoxylated sorbitan stearate, palmitate, oleate, nonyl phenol ethoxylates and fatty alcohol ethoxylates, and mixtures of two or more thereof. Thus, for example, Polysorbate 60 (a mixture of partial stearic esters of sorbitol and its anhydrides copolymerised with approximately 20 moles of ethylene oxide for each mole of sorbitol and its anhydrid s) has been found to b particularly pref rred. Th surfac active agent nhances th fatty alcohol solubility in th syst m and nhances foam formation.

The propellant used may be chosen from conventional aerosol propellants. Thus, one may select the propellant from propane, butane, dichloro difluoro methane, dichloro tetrafluoro ethane, octafluoro cyclobutane, and mixtures of two or more thereof. It is necessary to select a propellant most compatible with the entire system. It is particularly preferred that the propellant be present in amounts preferably of 3-30% w/w, more preferably 3-10% w/w, especially 3-5% w/w. The maximum level of propellant will be determined as the amount miscible with the utilized water/aliphatic alcohol ratio. In addition to acting as a propellant, the propellant will also act as a solvent for the fatty acids and active substances in the aqueous/alcoholic system.

It is possible that other additives may be used. Thus, it is preferred to add a humectant to reduce the drying effects of the aqueous aliphatic alcohol. Such a humectant may preferably be present in an amount of 0.1-10.0% w/w, more preferably 0.5-3.0% w/w. It is particularly preferred that the humectant be propylene glycol, but other humectants such as glycerine, panthenol and sorbitol may be used.

The composition of the present invention may be used to deliver corticosteroid compounds which have utility in the topical treatment of skin disorders. Thus, for example, the composition of the present invention may be used to deliver the following topically-effective corticosteroids:

alclometasone dipropionate  
amcinonide  
beclamethasone dipropionate  
betamethasone benzoate  
betamethasone dipropionate  
betamethasone valerate  
budesonide  
clobetasol propionate

fluclorolone acetonide  
fluocinolone acetonide  
fluocinonide  
fluocortin butyl  
fluocortolone preparations  
fluprednidene acetate  
flurandrenolone  
halcinonide

cl betasone butyrate	hydr cortison
desonide	hydrocortisone acetate
desoxymethasone	hydrocortisone butyrate
diflorasone diacetate	methylprednisolone acetate
difluocortolone valerate	mometasone furoate
flumethasone pivalate	triamcinolone acetonide

and pharmacologically effective mixtures thereof.

Compositions according to the invention are especially advantageous for the topical administration to the skin of human subjects of betamethasone and its derivatives such as betamethasone benzoate, betamethasone dipropionate, and betamethasone valerate. It is particularly preferred to use the valerate ester, especially in the treatment of psoriasis.

The corticosteroid active substance is preferably present in an amount of 0.01-1.0% w/w more preferably 0.05-0.2% w/w.

In view of the complexity of the composition, it has been found that unexpectedly in order to ensure stability of the active isomer of the corticosteroid in the composition and thus to ensure delivery of the most active isomer to the epidermis, it is necessary to buffer the composition by including a suitable buffering agent. Suitable buffering agents are acetic acid/sodium acetate, citric acid/sodium citrate and phosphoric acid/sodium phosphate, and it is desirable generally to buffer the composition to pH 3.0-6.0, preferably 4.0-5.0 and to this end the buffering agent may preferably be present in an amount of 0.01-1.0% w/w, more preferably 0.05-0.2% w/w. It is particularly preferred to use a citrate buffer system, more preferably anhydrous citric acid/potassium citrate, to buffer the composition to pH 4.5, when betamethasone valerate is used as the active substance; in this case citrate buffering stabilises the more active 17-

valerate ester over the less active 21-valerate ester in the complex composition and ensures that the most effective form of the active substance is efficiently delivered to the epidermis.

Preparation of the composition may be effected by conventional means so as to produce a homogeneous solution of fatty alcohol(s) (wax(es)) in an alcohol/water base. The relative proportions of the fatty alcohol(s), water/aliphatic alcohol and propellant are conveniently controlled according to conventional means so as to provide a homogeneous clear solution and so as to provide a homogeneous clear solution and so as to allow the formation of a suitable quick-break foam. Generally speaking the fatty alcohol(s), surface active agent, aliphatic alcohol and humectant (if present) are preferably mixed together with the corticosteroid active substance to produce an "Alcohol Phase". An "Aqueous Phase" is preferably produced by mixing the buffering agent and water. These phases are then mixed, preferably in the final container, in the required amounts. The propellant is then added under pressure to produce the composition according to the invention.

In the case of betamethasone valerate, for example, it is particularly preferred to use a composition comprising cetyl alcohol and octadecan-1-ol as fatty alcohols, together with Polysorbate 60 surface active agent, with purified water and ethanol as the aliphatic alcohol. The system is preferably buffered with anhydrous citric acid/potassium citrate and the propellant is preferably butane/propane. It is generally preferred to choose the proportion of the components to achieve a fixed pressure in the container of around 50-70 psi.

The composition of the present invention may be contained in and dispensed from a container capable of withstanding the pressure of the propellant gas and having an appropriate valve/nozzle for dispensing the composition as a foam under pressure. If the container is made of a material



material likely to suffer corrosion under the action of the composition, the composition may include a corrosion inhibitor as an additive. Thus, the presence of a corrosion inhibitor may be necessary if the container is made of tin plate. Suitable corrosion inhibitors include organic acid salts, preferably chosen from sorbic acid, benzoic acid, sodium benzoate and potassium sorbate. If used, the corrosion inhibitor may be present in amounts of 0.1-15% w/w, more preferably 0.1-3% w/w. In the present invention, aluminium cans are preferred as containers, particularly when utilising the above-mentioned composition for betamethasone valerate as the corticosteroid active substance; in this case there is no corrosion problem and there is no need for the inclusion of a corrosion inhibiting agent.

In use, the composition is sprayed, producing a semi-solid form (a foam or mousse) which is suitable for the topical application to the site of interest, eg the scalp when treating dermatological conditions of the scalp. On application, heat from the skin causes the mousse to break down into liquid form, thus releasing the aliphatic alcohol and corticosteroid active substance which penetrate the skin site, leaving a low amount of residue, many times lower than those obtained when delivering active from a cream base. This route of administration facilitates the ease of specific local application, and the composition according to the invention provides a convenient, controllable and efficient vehicle for delivering topically active corticosteroids to the skin. This gives greater physical control compared to conventional topical corticosteroid formulations, minimises rubbing of the target site and allows the alcoholic vehicle to penetrate the skin to deliver the active to where it will have the greatest effect.

The composition of the present invention may be used in treating skin diseases which are conventionally treated with corticosteroid active substances. Thus, the composition may be used in the treatment of, inter alia, eczema, infantile eczema, atopic dermatitis, dermatitis herpetiformis, contact dermatitis, seborrhoeic dermatitis, neurodermatitis, psoriasis and

intertrigo. The composition is especially useful in the treatment of scalp psoriasis in human subjects.

The present invention will now be illustrated by means of the following non-limiting Example:

### EXAMPLE

#### Betamethasone valerate composition

A betamethasone valerate formulation having the following composition was prepared:

	<u>% w/w</u>
— Betamethasone Valerate	0.12
— Cetyl Alcohol BP	1.10
— Octadecan-1-ol BP	0.50
— Polysorbate 60 BP	0.40
— Ethanol	57.79
— Purified Water	33.69
— Propylene Glycol BP	2.00
— Citric Acid Anhydrous BP	0.073
— Potassium Citrate	0.027
— Butane/Propane	4.30
	-----
	100.00

Cetyl alcohol (HYFATOL 1698, Efka Chemicals Limited, London), octadecan-1-ol (HYFATOL 1898, Efka Chemicals Limited, London), Polysorbate 60 (CRILLET 3, Croda Chemicals, North Humberside) and ethanol in the correct proportions were mixed and heated to about 45°C,

with continuous stirring until the mix b came clear. Betam thasone valerate BP (Roussel Uclaf, Virtolaye, France) was slowly transferred into the mix, again with continuous stirring until the mix became clear. (Alcoholic Phase)

Purified water was separately heated to 45°C and anhydrous citric acid BP and potassium citrate BP transferred to the water, with continuous stirring until dissolved. (Aqueous Phase)

The Alcoholic and Aqueous phases were each filtered through 75 micron screens and the required weights filled into a can (aluminium, epoxy lined) at room temperature. After attaching a valve, the butane/propane propellant (Propellant P70) was added to the mix in the can to the required weight, and an actuator added to the valve.

The composition, on being sprayed from the can onto the skin, produces a thermophobic foam which breaks down under heating from the skin to release the active to the epidermis. The presence of the citrate buffer stabilizes the 17-valerate configuration of the betamethasone valerate over the less active 21-valerate configuration, thus producing a composition which efficaciously delivers active to the epidermis and which is particularly suitable for the treatment of psoriasis, especially scalp psoriasis.

**CLAIMS**

1. A foamable pharmaceutical composition comprising a corticosteroid active substance, a quick-break foaming agent, a propellant and a buffering agent.
2. A foamable pharmaceutical composition comprising a quick-break foaming agent, a propellant, a buffering agent, and a corticosteroid active substance, the corticosteroid steroid active substance being of a type which exhibits isomerism and has a more active isomer and a less active isomer, the corticosteroid active substance being present as the more active isomer, and the buffering agent being present in an amount effective to stabilise the more active isomer against isomerisation to the less active isomer.
3. A foamable pharmaceutical composition according to Claim 1 or Claim 2 which is buffered to a pH in the range 3.0 to 6.0.
4. A foamable pharmaceutical composition according to Claim 3 which is buffered to a pH in the range 4.0 to 5.0.
5. A foamable pharmaceutical composition according to any one of the preceding Claims wherein the buffering agent is present in an amount from 0.01 to 1.0% w/w.
6. A foamable pharmaceutical composition according to Claim 5 wherein the buffering agent is present in an amount in the range 0.05 to 0.2% w/w.
7. A foamable pharmaceutical composition according to any one of the preceding Claims wherein the buffering agent is selected from acetic acid/sodium acetate buffer, citric acid/sodium citrate

buffer and phosphoric acid/sodium phosphate buffer.

8. A foamable pharmaceutical composition according to any one of the preceding Claims wherein the corticosteroid active substance is a topically effective corticosteroid selected from:

alclometasone dipropionate	fluclorolone acetonide
amcinonide	fluocinolone acetonide
beclamethasone dipropionate	fluocinonide
betamethasone benzoate	fluocortin butyl
betamethasone dipropionate	fluocortolone preparations
betamethasone valerate	fluprednidene acetate
budesonide	flurandrenolone
clobetasol propionate	halcinonide
clobetasone butyrate	hydrocortisone
desonide	hydrocortisone acetate
desoxymethasone	hydrocortisone butyrate
diflorasone diacetate	methylprednisolone acetate
difluocortolone valerate	mometasone furoate
flumethasone pivalate	triamcinolone acetonide

and pharmacologically effective mixtures thereof.

9. A foamable pharmaceutical composition according to any one of the preceding Claims wherein the corticosteroid active substance is betamethasone or a derivative thereof.
10. A foamable pharmaceutical composition according to Claim 9 wherein the corticosteroid active substance is selected from betamethasone benzoate, betamethasone dipropionate and betamethasone valerate.
11. A foamable pharmaceutical composition according to Claim 10 wherein the corticosteroid active substance is betamethasone valerate.

12. A foamable pharmaceutical composition according to any one of the preceding Claims wherein the corticosteroid active substance is present in an amount from 0.01 to 1.0% w/w.
13. A foamable pharmaceutical composition according to Claim 12 wherein the corticosteroid active substance is present in an amount from 0.5 to 0.2% w/w.
14. A foamable pharmaceutical composition according to any one of the preceding Claims wherein the quick-break foaming agent comprises an aliphatic alcohol, water, a fatty alcohol and a surface active agent.
15. A foamable pharmaceutical composition according to Claim 14 wherein the aliphatic alcohol is present in an amount corresponding to 40 to 90% by weight of the total weight of the composition.
16. A foamable pharmaceutical composition according to Claim 15 wherein the aliphatic alcohol is present in an amount corresponding to 55 to 70% by weight of the composition.
17. A foamable pharmaceutical composition according to Claim 16 wherein the aliphatic alcohol is present in an amount corresponding to 57 to 59% by weight of the composition.
18. A foamable pharmaceutical composition according to any one of Claims 14 to 17 wherein the aliphatic alcohol is selected from methanol, ethanol, isopropyl alcohol, and butyl alcohol and mixtures of two or more thereof.
19. A foamable pharmaceutical composition according to Claim 18 wherein the aliphatic alcohol is ethanol.

20. A foamable pharmaceutical composition according to any one of Claims 14 to 19 wherein the water is present in an amount in the range 10 to 40% by weight of the composition.
21. A foamable pharmaceutical composition according to any one of Claims 14 to 20 wherein the fatty alcohol is present in an amount corresponding to 0.5 to 10% by weight of the composition.
22. A foamable pharmaceutical composition according to any one of Claims 14 to 21 wherein the fatty alcohol is selected from cetyl, stearyl, lauryl, myristyl and palmityl alcohols and mixtures of two or more thereof.
23. A foamable pharmaceutical composition according to Claim 22 wherein the fatty alcohol is a mixture of cetyl alcohol and a stearyl alcohol.
24. A foamable pharmaceutical composition according to any one of Claims 14 to 23 wherein the surface active agent is present in an amount from 0.1 to 15% w/w of the composition.
25. A foamable pharmaceutical composition according to any one of Claims 14 to 24 wherein the surface active agent is selected from an ethoxylated sorbitan stearate, palmitate, oleate, nonyl phenol or fatty alcohol, and mixtures of two or more thereof.
26. A foamable pharmaceutical composition according to Claim 25 wherein the surface active agent is a mixture of partial stearic esters of sorbitol and its anhydrides copolymerised with approximately 20 moles of ethylene oxide for each mole of sorbitol and its anhydrides.
27. A pharmaceutical product comprising a foamable pharmaceutical composition according to any one of the preceding Claims containing d

within a container capable of withstanding the pressure of the propellant gas, and having a valve or nozzle for dispensing the foamable composition as a foam under pressure.

28. A foamable pharmaceutical composition according to Claim 1 having the following composition:

	<u>% w/w</u>
Betamethasone Valerate	0.12
Cetyl Alcohol BP	1.10
Octadecan-1-ol BP	0.50
Polysorbate 60 BP	0.40
Ethanol	57.79
Purified Water	33.69
Propylene Glycol BP	2.00
Citric Acid Anhydrous BP	0.073
Potassium Citrate	0.027
Butane/Propane	4.30
	-----
	100.00

29. A foamable pharmaceutical composition according to any one of Claims 1 to 27, or a pharmaceutical product according to Claim 28, for use in the treatment of eczema, infantile eczema, atopic dermatitis, dermatitis herpetiformis, contact dermatitis, seborrhoeic dermatitis, neurodermatitis, psoriasis and intertrigo.
30. A foamable pharmaceutical composition or pharmaceutical product according to claim 29 for use in the treatment of scalp psoriasis.
31. A method of treatment of a skin disease susceptible to treatment with corticosteroid active substances, which method comprises administering topically to a patient in need thereof an effective



an unit of a foamable pharmaceutical composition as defined in any one of Claims 1 to 26, or a pharmaceutical product as defined in Claim 27.

32. A method according to Claim 31 wherein the skin disease is selected from eczema, infantile eczema, atopic dermatitis, dermatitis herpetiformis, contact dermatitis, seborrhoeic dermatitis, neurodermatitis, psoriasis and intertrigo.
33. A method according to Claim 32 for treating scalp psoriasis in human subjects.

## INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/GB 96/00490

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K31/57 A61K9/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 484 530 (HISAMITSU PHARMACEUTICAL) 13 May 1992 see claims 1-3 see page 3, line 40 - page 4, line 50 ---	1-33
A	US,A,4 018 918 (THE UPJOHN COMPANY) 19 April 1977 see claim 1 see column 11, line 3 - column 12, line 11 ---	1-33
A	EP,A,0 423 695 (STERLING DRUG) 24 April 1991 see claims 1,2 see page 2, line 50 - page 4, line 6 --- -/--	1-33

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*A\* document member of the same patent family

Date of the actual completion of the international search

10 June 1996

Date of mailing of the international search report

21.06.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 96/00490

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO,A,85 01876 (LOCKLEY SERVICES) 9 May 1985  cited in the application  see claims 1-16  -----</p>	1-33

# INTERNATIONAL SEARCH REPORT

Int. application No.

PCT/GB96/00490

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 29-33 are directed to a method of treatment of the  
human body the search has been carried out and based on the alleged  
effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such  
an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 96/00490

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-484530	13-05-92	DE-D- 69020900	17-08-95
		DE-T- 69020900	14-12-95
		KR-B- 9502879	28-03-95
		US-A- 5352437	04-10-94
		AT-T- 124860	15-07-95
		AU-B- 629670	08-10-92
		AU-B- 6033190	11-03-91
		CA-C- 2042583	20-06-95
		WO-A- 9101712	21-02-91
US-A-4018918	19-04-77	US-A- 3980778	14-09-76
		BE-A- 852649	19-09-77
		DE-A- 2710880	29-09-77
		FR-A- 2344288	14-10-77
		GB-A- 1527061	04-10-78
		JP-A- 52113954	24-09-77
		NL-A- 7702822	21-09-77
EP-A-423695	24-04-91	AU-B- 6463490	26-04-91
		CA-A- 2027952	20-04-91
		JP-A- 3255023	13-11-91
		US-A- 5378451	03-01-95
WO-A-8501876	09-05-85	AU-B- 565146	03-09-87
		AU-B- 3506184	22-05-85
		EP-A- 0160051	06-11-85
		JP-B- 6096522	30-11-94
		JP-T- 61500357	06-03-86
		US-A- 4915934	10-04-90
		US-A- 4981678	01-01-91